Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-07-21 , DOI: 10.1111/1759-7714.14075
Minjiang Chen ₁ , Yan Xu ₁ , Jing Zhao ₁ , Ji Li ₂ , Xiangning Liu ₁ , Wei Zhong ₁ , Mengzhao Wang ₁

Affiliation

Programmed cell death ligand-1 (PD-L1) is a useful biomarker in non-small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD-L1 expression. In this study, we evaluated the feasibility and reliability of PD-L1 testing on small biopsy samples.

中文翻译：

使用小活检标本评估非小细胞肺癌 PD-L1 表达测定的可行性和可靠性

程序性细胞死亡配体 1 (PD-L1) 是可能受益于免疫治疗的非小细胞肺癌 (NSCLC) 患者的有用生物标志物。在大多数晚期 NSCLC 患者中，只有少量活检标本可用于评估 PD-L1 表达。在这项研究中，我们评估了 PD-L1 检测对小活检样本的可行性和可靠性。

更新日期：2021-09-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11